ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Ascletis Pharma, Inc. ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
- Poor long term growth as Net Sales has grown by an annual rate of -55.39% and Operating profit at -194.80% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -321.54
2
Flat results in Jun 25
- OPERATING CASH FLOW(Y) Lowest at HKD -501.37 MM
- RAW MATERIAL COST(Y) Grown by 1,466.05% (YoY)
- CASH AND EQV(HY) Lowest at HKD 1,968.27 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 594.74%, its profits have fallen by -85.6%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Ascletis Pharma, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Ascletis Pharma, Inc.
598.08%
9.98
117.57%
Hang Seng Hong Kong
27.36%
1.03
25.88%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-55.39%
EBIT Growth (5y)
-194.80%
EBIT to Interest (avg)
-321.54
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.47
EV to EBIT
-24.88
EV to EBITDA
-26.12
EV to Capital Employed
137.67
EV to Sales
4416.80
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-553.35%
ROE (Latest)
-15.73%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend2What is working for the Company
NET PROFIT(HY)
Higher at HKD -134.49 MM
-5What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at HKD -501.37 MM
RAW MATERIAL COST(Y)
Grown by 1,466.05% (YoY
CASH AND EQV(HY)
Lowest at HKD 1,968.27 MM
Here's what is working for Ascletis Pharma, Inc.
Net Profit
Higher at HKD -134.49 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (HKD MM)
Here's what is not working for Ascletis Pharma, Inc.
Operating Cash Flow
Lowest at HKD -501.37 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (HKD MM)
Cash and Eqv
Lowest at HKD 1,968.27 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Raw Material Cost
Grown by 1,466.05% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
